EU Finds Lundbeck Pay-For-Delay Deals Blocked Generics
The European Commission accused Danish drugmaker H. Lundbeck A/S and others on Wednesday of violating EU antitrust rules by inking so-called pay-for-delay deals with generic competitors to keep cheaper versions of...To view the full article, register now.
Already a subscriber? Click here to view full article